Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862648 | 1.00 | EIF2AK2 (0.55) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL5448079 | 0.85 | EIF2AK2 (0.55) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL30353413 | 0.83 | BACE1 (0.62) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL1804320 | 0.83 | BACE1 (0.62) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL30353445 | 0.83 | BACE1 (0.62) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL3864311 | 0.83 | ERN1 (0.58) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL924598 | 0.83 | TDO2 (0.55) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL924601 | 0.83 | TDO2 (0.55) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL1804321 | 0.83 | BACE1 (0.62) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 | |
| SCHEMBL3864314 | 0.83 | ERN1 (0.58) | EIF2AK2CSNK2A2CSNK2BCSNK2A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-1355878-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6632825-B2 | Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives | AGOURON PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001096297-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | EIF2AK2 212/4885CSNK2A2 2480/4885CSNK2B 2062/4885 |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNASEL, RNASEH1 | EIF2AK2 169/4885CSNK2A2 2486/4885CSNK2B 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.